MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended October 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.25 per share a year ago.
Medtronic lifted the lower end of its annual profit forecast for a second time, banking on sustained demand for its medical devices in the U.S. and sending its shares up nearly 2% in premarket trading on Tuesday.
The latest trading day saw Medtronic (MDT) settling at $87.53, representing a +1.78% change from its previous close.
Besides Wall Street's top -and-bottom-line estimates for Medtronic (MDT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024.
A Beverly Hills surgeon is suing Medtronic claiming patent infringement of her hernia repair mesh product. It's the latest in a series of patent challenges against Medtronic.
The latest trading day saw Medtronic (MDT) settling at $87.72, representing a -0.45% change from its previous close.
Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.
These are the kinds of stocks that can allow investors to sleep easy at night.
Medtronic (MDT) reachead $90.07 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
In the most recent trading session, Medtronic (MDT) closed at $90.60, indicating a +0.01% shift from the previous trading day.